OPTIMIZATION AND SOLUBILIZATION STUDY OF NANOEMULSION BUDESONIDE AND CONSTRUCTING PSEUDOTERNARY PHASE DIAGRAM

  • Raman Kumar Puppala Department of Pharmaceutical Technology, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India. http://orcid.org/0000-0003-2967-1476
  • Vijaya Lakshmi A Department of Pharmaceutical Technology, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Chennai, Tamil Nadu, India.

Abstract

Objective: The aim of the present study was to formulate and optimize budesonide nanoemulsions for targeting inflammation.

Methods: Budesonide is only found in individuals that have used or taken this drug. It is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. The exact mechanism of the action of budesonide in the treatment of Crohn’s disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect. The formulation was optimized for different components and the solubility study for the oil in surfactant and cosurfactant mix ratio was optimized using ternary phase diagram.

Results: The surfactant mix ratio was optimized as 1:3 where the maximum concentration of the oil has solubilized and the nanoemulsion area was increased.

Conclusion: Budesonide nanoemulsion for targeting inflammation and the pseudoternary phase diagram for the solubility studies and the components of different phases were optimized and achieved through this study.

Keywords: Nanoemulsion, Budesonide, Pseudoternary phase diagram solubility, Anti-inflammatory effect.

References

1. Malothu N, Veldandi UK, Yellu NR, Yadala N, Devarakonda RK, Chaudhary A. Population pharmacokinetics of budosenide In Indian Chris’s disease patient population. Asian J Pharm Clin Res 2010;3:3-24.
2. Maha HL, Sinaga KR, Fria M. Formulation and evaluation of miconazole nitrate nanoemulsion and cream. Asian J Pharma Clin Res 2018;11:319-21.
3. Chaudhari PM, Kuchekar MA, Laxmi M, Bhardwaj A, Mehta S, Mehta A. Development and evaluation of nanoemulsion as a carrier for topical delivery system by box-behnken design. Asian J Pharm Clin Res 2018;11:286-93.
4. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
5. Tenjarla S. Microemulsions: An overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 1999;16:461-521.
6. Courrier H, Krafft MP, Nakamura S, Shibata O, Vandamme T. Water-in-fluorocarbon reverse emulsion as a pulmonary drug delivery system: Effect on the lung as modelled by a phospholipid monolayer. S T P Pharma Prat 2003;13:22-6.
7. Patel N, Marlow M, Lawrence MJ. Formation of fluorinated nonionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 134a). J Colloid Interface Sci 2003;258:345-53.
8. Patel N, Marlow M, Lawrence MJ. Fluorinated ionic surfactant microemulsions in hydrofluorocarbon 134a (HFC 134a). J Colloid Interface Sci 2003;258:354-62.
9. Sommerville ML, Hickey AJ. Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsions. AAPS Pharm Sci Tech 2003;4:E58.
10. Sommerville ML, Johnson CS Jr. Cain JB, Rypacek F, Hickey AJ. Lecithin microemulsions in dimethyl ether and propane for the generation of pharmaceutical aerosols containing polar solutes. Pharm Dev Technol 2002;7:273-88.
11. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: A review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000;60:1141-78.
12. Ali HS, York P, Blagden N, Soltanpour S, Acree WE Jr., Jouyban A. Solubility of budesonide, hydrocortisone, and prednisolone in ethanol + water mixtures at 298.2 K. J Chem Eng Data 2010;55:578-82.
13. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999;54:691-9.
14. Meloche CA, Sharma V, Swedmark S, Andersson P, Falany CN. Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos 2002;30:582-5.
15. Piao HM, Cho HJ, Oh EC, Chung SJ, Shim CK, Kim DD. Budesonide microemulsions for enhancing solubility and dissolution rate. J Korea Pharm Sci 2009;39:417-22.
16. Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, et al. Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles. Anticancer Res 2009;29:1009-14.
17. Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm 2007;57:315-32.
18. Shafiq S, Faiyaz S, Sushma T, Farhan JA, Khar RH, Ali M. Design and development of ramipril nanoemulsion formulation: In vitro and in vivo assessment. J Biomed Nanotechnol 2007;3:28-44.
19. Shafiq S, Faiyaz S, Sushma T, Farhan JA, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007;66:227-43.
20. Jain J, Fernandes C, Patravale V. Formulation development of parenteral phospholipid-based microemulsion of etoposide. AAPS PharmSciTech 2010;11:826-31.
21. Rowe RC, Sheskey PJ, Weller PJ, editor. Handbook of Pharmaceutical Excipients. 4th ed. Washington: Pharmaceutical Press, London/ American Pharmaceutical Association; 2003.
22. Shafiq-un-Nabi S, Shakeel F, Talegaonkar S, Ali J, Baboota S, Ahuja A, et al. Formulation development and optimization using nanoemulsion technique: A technical note. AAPS PharmSciTech 2007;8:28.
Statistics
66 Views | 142 Downloads
How to Cite
Puppala, R. K., and V. L. A. “OPTIMIZATION AND SOLUBILIZATION STUDY OF NANOEMULSION BUDESONIDE AND CONSTRUCTING PSEUDOTERNARY PHASE DIAGRAM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 1, Jan. 2019, pp. 551-3, doi:10.22159/ajpcr.2019.v12i1.28686.
Section
Original Article(s)